Use of polaprezinc in preparing drug for treating castration-resistant prostate cancer

Patent metadata

Field	Value
Publication number	US-12533361-B2
Application number	US-202217829633-A
Country	US
Kind code	B2
Filing date	Jun 1, 2022
Priority date	May 8, 2021
Publication date	Jan 27, 2026
Grant date	Jan 27, 2026

Abstract

The present disclosure discloses use of polaprezinc (Pola) in preparing a drug for treating castration-resistant prostate cancer (CRPC) and belongs to the technical field of biological medicine. The present disclosure provides a new strategy for preparing the drug for treating the CRPC by combining the Pola with an androgen receptor antagonist for the first time and conducts a multi-angle and multi-level verification research. A drug composition combining the polaprezinc and the androgen receptor antagonist can be used for treating castration-resistant prostate cancer, remarkably improves an effect of enzalutamide in inhibiting the castration-resistant prostate cancer, realizes new use of the old drug, can greatly shorten time from drug discovery to clinical transformation, and has important clinical treatment significance.

First claim

What is claimed is:

1 . A method of preparing a EPI and enza-resistant and castration-resistant prostate cancer drugs, which comprises:
providing the castration-resistant prostate cancer drugs enzalutamide and EPI; and adding polaprezinc to the castration resistant prostate cancer drugs, wherein the castration-resistant prostate cancer drugs and the polaprezinc are present at a mass ratio of (1 to 5):1, respectively.

2 . A method of treating EPI and Enza-resistant castration-resistant prostate cancer, which comprises administering an effective amount of the composition prepared by the method of claim 1 to a patient in need thereof,
wherein the patient has EPI and Enza-resistant castration-resistant prostate cancer.

3 . The composition prepared by the method of claim 1 .

4 . The drug composition according to claim 3 , wherein the composition further comprises a pharmaceutical auxiliary material.

5 . The composition according to claim 4 , wherein the pharmaceutical auxiliary material comprises one or more of a solvent, a propellant, a solubilizer, a cosolvent, an emulsifier, a colorant, a binding agent, a disintegrant, a filler, a lubricant, a wetting agent, an osmotic pressure regulator, a stabilizer, a flow aid, a corrigent, a preservative, a suspending agent, a coating material, an aromatic, an anti-binding agent, a chelating agent, a penetration enhancer, a pH regulator, a buffering agent, a plasticizer, a surfactant, a foaming agent, an antifoaming agent, a thickener, a clathrating agent, a humectant, an absorbent, a diluent, a flocculant, a deflocculant, a filter aid, and a release retardant.

6 . The composition according to claim 3 , wherein the composition further comprises a carrier.

7 . The composition according to claim 6 , wherein the carrier comprises one or more of a microcapsule, a microsphere, a nanoparticle, and a liposome.

8 . The composition according to claim 3 , wherein the composition is in a dosage form of an injection, a lyophilized powder for injection, a controlled release injection, a liposome injection, a suspension, an implant, an embolic agent, a capsule, a tablet, a pill, or an oral liquid.

Assignees

• Univ Jiangnan

Inventors

• Wang Rong
• Chen Yongquan
• Zhu Shenglong
• Wang Xiaoying
• Mi Yuanyuan
• Wu Sheng
• Sun Jian

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/58 Primary

  containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048}) · CPC title

• A61K31/502

  ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine · CPC title

• A61K31/4166

  having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin · CPC title

• A61K31/555 Primary

  containing heavy metals, e.g. hemin, hematin, melarsoprol · CPC title